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We recently demonstrated that sildenafil reduces the expression of cytokines, COX-2, and GFAP in a demyelinating model induced
in wild-type (WT) mice. Herein, the understandings of the neuroprotective effect of sildenafil and the mediation of iNOS/NO
system on inflammatory demyelination induced by cuprizone were investigated. The cerebella of iNOS−/− mice were examined
after four weeks of treatment with cuprizone alone or combined with sildenafil. Cuprizone increased GFAP, Iba-1, TNF-𝛼, COX-2,
IL-1𝛽, and IFN-𝛾 expression, decreased expression of glutathione S-transferase pi (GSTpi), and damaged myelin in iNOS−/− mice.
Sildenafil reduced Iba-1, IFN-𝛾, and IL-1𝛽 levels but had no effect on the expression of GFAP, TNF-𝛼, and COX-2 compared to the
cuprizone group. Sildenafil elevated GSTpi levels and improved the myelin structure/ultrastructure. iNOS−/− mice suffered from
severe inflammation following treatment with cuprizone, whileWTmice had milder inflammation, as found in the previous study.
It is possible that inflammatory regulation through iNOS-feedback is absent in iNOS−/− mice, making them more susceptible to
inflammation. Sildenafil has at least a partial anti-inflammatory effect through iNOS inhibition, as its effect on iNOS−/− mice was
limited. Further studies are required to explain the underlying mechanism of the sildenafil effects.
1. Background
Nitric oxide (NO) is a highly reactive molecule with a
range of physiological functions [1, 2]. This messenger plays
an important role in the modulation of vascular tone [3],
neurotransmission [4, 5], and immune system [6–8]. NO
is produced from L-arginine by NO synthases (NOSs). In
addition to the constitutive forms of the enzyme (endothelial
(eNOS or NOS3) and neuronal (nNOS or NOS1)), there is
also an inducible form (iNOS or NOS2). This last is most
commonly associatedwith inflammatory conditions inwhich
NO is produced in large amounts.
There is strong evidence to suggest the involvement
of iNOS in the development of neurodegenerative disease.
Induction of iNOS, NO, and NO byproducts has been found
in multiple sclerosis (MS) patients and animal models and
correlates with disease severity and level of inflammatory
infiltrate [9–12]. Interestingly, however, iNOS-deficient mice
developed a more severe MS model [13, 14]. It was found that
the elimination of iNOS does not improve, and may actually
aggravate, demyelination in the cuprizone-demyelinating
model [15], which suggests that the iNOS/NO systemmay be
neuroprotective. More information is required to understand
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the role of iNOS/NO in inflammatory response, oligodendro-
cyte cell death, and myelin damage/loss.
The cyclic guanosine 3󸀠,5󸀠-monophosphate (cGMP) sig-
naling pathway is an important NO-signaling molecule. NO
binds to soluble guanylyl cyclase (sGC) and increases concen-
tration of cGMP, activating signaling cascades and leading to
cGMP-dependent responses [16, 17].The cGMP signal can be
terminated by the action of several phosphodiesterases (PDE)
[18].The cGMP-selective PDE5 is expressed in the cardiovas-
cular, neural, and immune systems [18]. Studies have shown
that selective PDE5 inhibitors, widely used in the treatment
of erectile dysfunction in humans, such as sildenafil (Viagra;
Pfizer) and vardenafil (Levitra; Bayer), raise cGMP levels in
the brain and offer protective effects, improve cognition and
memory [19], reduce neuronal cell death following ischemic
cerebrovascular injury [20], decrease white matter damage,
and regulate inflammatory responses in MS models [21, 22].
Recent studies by the authors of an MS model induced in
wild-type C57BL6 mice found that sildenafil has an anti-
inflammatory action, reducing levels of proinflammatory
cytokines and cyclooxygenase-2 (COX-2) and protecting the
myelin structure [22]. However, the mechanism of sildenafil
neuroprotection remains unknown.
In the present study, inflammatory demyelination was
induced in iNOS−/−mice, and sildenafil was administered for
four weeks. The focus of this study was to identify the role
of a potent inflammation-associatedmolecule, iNOS-derived
NO, in protective mechanisms related to sildenafil. The
present study also aimed to clarify the role of NO protective
and/or deleterious mechanisms in the demyelinating model.
2. Materials and Methods
2.1. Experimental Design. Five iNOS knockout (B 6.129 P2-
Nos2) mice, aged 7 to 10 weeks, weighing 15 to 20 g, were
used per group. The mice were examined for health status,
acclimated to the laboratory environment at 25∘C and 12 h
light/dark photoperiod, and housed in metal cages. The con-
trol group received standard laboratory diet and pure water.
Over a four-week period, the experimental groups received
either 0.2% cuprizone (oxalic-bis-cyclohexylidenehydrazide
Sigma-Aldrich Inc., St. Louis, MO, USA) mixed into the
chow and pure water or 0.2% cuprizone in the chow and
25mg/kg of bodyweight of sildenafil (Viagra; Pfizer Inc., New
York, NY, USA) administered through the drinking water
[22–24]. Body weight was accessed every week and the drug
concentration in the water was adjusted tomaintain the dose.
All experiments were carried out in compliance with ethical
guidelines for animal experimentation (L-10/2010-CEUA;
05/10-CIBIO FIOCRUZ). After treatment, the animals were
anaesthetized (i.m.) with ketamine (115mg/kg) and xylazine
(10mg/kg) (Sespo Come´rcio e Indu´stria Ltda., Sa˜o Paulo, SP,
Brazil).
2.2. Immunofluorescence (IF). After anesthesia, the ani-
mals were transcardially perfused with physiological saline
(20mL), followed by 4% paraformaldehyde (Sigma-Aldrich)
(40mL) in 0.1M phosphate (sodium phosphate monobasic
and dibasic heptahydrate, Sigma-Aldrich) buffered saline
(PBS), pH 7.2. Cerebella were dissected and immersed in
15% sucrose overnight, followed by 30% sucrose for a second
night (36 hours total). The specimens were then embedded
in OCT-Tissue Tek compound (Sakura Finetek, Torrance,
CA, USA) and frozen in n-hexane (Dinaˆmica, Sa˜o Paulo,
SP, Brazil) cooled with liquid nitrogen. Cryosections (8𝜇m
thick) were permeabilized (0.3%Triton X-100) and incubated
for 1 h with blocking solution (3% BSA plus 0.2% Tween
20 in Tris buffered saline). Subsequently, the sections were
incubated with antibodies for Glial Fibrillar Acidic Pro-
tein (GFAP) (DakoCytomation, cat. no. ZO 334) and Iba-1
(Wako, Osaka, Japan, cat. no. 019-19741) (both 1 : 100). Sec-
tions were incubated with primary antibodies overnight and
then incubated with polyclonal Cy3-conjugated secondary
antibodies (Jackson, cat. no. 705-165-147) against rabbit
immunoglobulin (1 : 200) for 1 h. The slides were washed
and mounted in fluorescent Prolong Gold Antifade medium
(Life Technologies, cat. no. P36930) for observation under
an inverted fluorescence microscope (Zeiss MicroImaging
GmbH) equipped with a camera (Zeiss AxioCamMRM) and
the Release 4.7.2 image analysis software.
2.3. Immunohistochemistry (IH). After perfusion as de-
scribed for IF, cerebella were immediately removed and
postfixed in the same fixative overnight. The samples were
dehydrated in an ethanol series (Isofar Chemical Co., RJ,
Brazil), cleared in xylene, and embedded in paraffin (Merck,
catalog no. 1071642504). Sections (5𝜇m thick) were cut on an
RM 2035 microtome (Reichert S, Leica), rehydrated, washed
in 0.05M PBS, and incubated in this buffer with 1% bovine
serum albumin (BSA, fraction V) (Miles, Naperville, IL,
USA) for one hour. Endogenous peroxidase was blocked
and antigen retrieval was performed, pretreating the sec-
tions with 20mM citrate buffer, pH 6.0, at 100∘C, for
30min. All groups were incubated with the rabbit polyclonal
anti-COX-2 (Abcam, Canada/US, cat. no. ab15191) (1 : 100,
overnight at 4∘C). After washing, the sections were overlaid
for 1 h with a biotin-conjugated secondary antibody using
an HRP kit (DakoCytomation, CA, USA, Biotinylated Link
Universal HRP; cat. no. K0690) and visualized with 3󸀠-3-
diaminobenzidine (DAB) as the chromogen. The sections
were then weakly counterstained with Harris’ hematoxylin
and mounted in entellan (Merck, cat. no. 1079610100).
2.4.Western Blotting (WB). Cerebella were quickly dissected,
and each group was homogenized in an extraction cocktail
(10mM EDTA, Amresco, Solon, USA; 2mM phenylmethane
sulfonyl-fluoride, 100mM NaF, 10mM sodium pyrophos-
phate, 10mM NaVO
4
, 10 𝜇g of aprotinin/mL, and 100mM
Tris, pH 7.4). Cerebella of five animals were mixed and
homogenized to form a pool from each group. The WB was
done in accord with Nunes et al. [22]. Briefly, the pro-
teins (40 𝜇g total) were separated on 6.5% (IFN-𝛾), 10%
(TNF-𝛼, IL-1𝛽), or 12% (GFAP, eNOS) acrylamide gel.
After overnight in 5% nonfat milk, the primary antibodies
against GFAP (1 : 10,000, DakoCytomation, cat. no. ZO 334),
COX-2 (1 : 1000, Abcam, cat. no. ab15191), TNF-𝛼 (1 : 1000,
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Peprotech, NJ, USA, cat. no. 500-P64), IFN-𝛾 (1 : 2500,
Peprotech cat. no. 500P119), IL-1𝛽 (1 : 2500, GenWay Biotech,
Inc., CA/USA, cat. no. 18-732-292194), GST3/GSTpi (1 : 250,
Abcam, Canada, cat. no. ab53943), and eNOS (1 : 1000,
BD Biosciences, cat. no. 610299) were incubated for four
hours followed by horseradish peroxidase-conjugated anti-
bodies anti-rabbit (1 : 80,000, Sigma-Aldrich, cat. no. A9169),
anti-mouse (1 : 1,000, Sigma-Aldrich, cat. no. A0168), or
anti-goat secondary antibody (1 : 100,000, Sigma-Aldrich,
cat. no. A5420). For quantification, the pixel density of
each band was determined using the Image J 1.38 soft-
ware (http://rsbweb.nih.gov/ij/download.html; developed by
Wayne Rasband, NIH, Bethesda,MD,USA). For each protein
investigated, the results were confirmed in three sets of
experiments. Immunoblotting for 𝛽-actin (1 : 1,000, Sigma-
Aldrich, cat. no. A2228) was performed as a control.
2.5. Luxol Fast-Blue (LFB). After perfusion as described for
IF, the samples were dehydrated in a graded ethanol series,
cleared in xylene, and embedded in paraffin. Sections (5 𝜇m
thick) were cut on an RM 2035 microtome (Reichert S,
Leica). Myelin was detected using Luxol-Fast Blue (LFB)
staining (Solvent Blue 38; Sigma-Aldrich) in accord with
Nunes et al. [22]. The sections were observed under an
inverted microscope (Zeiss MicroImaging GmbH) equipped
with a camera (ZeissAxioCamMRM) andRelease 4.7.2 image
analysis software (Zeiss).
2.6. Transmission Electron Microscopy (TEM). After anes-
thesia, the animals were sacrificed by transcardial perfusion
with physiological saline (20mL), followed by 40mL of
fixative—2.5% glutaraldehyde and 4% paraformaldehyde in
0.1M sodium cacodylate acid (Sigma-Aldrich) buffer, pH
7.2. Cerebella were quickly dissected and postfixed in the
same fixative overnight. Next, cerebellum fragments were
washed twice in the same buffer and postfixed in a solution
containing 1% osmium tetroxide (Sigma-Aldrich), 2mM
calcium chloride, and 0.8% potassium ferricyanide (Sigma-
Aldrich) in 0.1M cacodylate buffer, pH 7.2, dehydrated in
acetone and embedded in SPIN-PON resin (Embed 812-
Electron Microscopy Science, Washington, PA, USA). Resin
polymerization was performed at 60∘C for 3 days. Semithin
sections (0.5 𝜇m in thickness) were placed on glass slides,
stained with toluidine blue. Ultrathin sections (70 nm in
thickness) were placed on 300-mesh nickel grids, counter-
stainedwith 5%uranyl acetate (ElectronMicroscopy Science)
and lead citrate (Sigma-Aldrich), and examined using a FEI
Morgagni 268D transmission electron microscope.
2.7. Statistical Analysis. The densitometric values of the
immunoreactive bands (immunoblotting) were analyzed
using the GraphPad Prism software package (San Diego,
CA, USA). One-way analysis of variance (ANOVA), followed
by Dunnett’s and/or Tukey’s posttest, was used to compare
groups. The results were expressed as means ± SE, when
appropriate. A𝑃 value< 0.05 indicated statistical significance.
3. Results
Clinical analysis revealed that cuprizone-treated animals
suffered frommotor limitations, such as tremors, and abnor-
mal walking and posture. The group treated with silde-
nafil (25mg/kg) exhibited normal walking and posture, and
tremors were either mild or nonexistent.
The clinical signs were observed and recorded by three
observers. The iNOS−/− control animals exhibited normal
motor function and posture and explored their environment
normally. This group was classified as score 0 (no sign). The
mice treated with cuprizone exhibited arched (shortened)
posture and tremors and had difficulty in exploring the
environment. This group was classified as score 2. Mice
treated with 25mg/kg of sildenafil both walked and were
able to explore the environment normally, with no or mild
tremors, and were classified as score 1.
Cuprizone increased GFAP, TNF-𝛼, and COX-2 expres-
sion in cerebellum, indicating astrocyte activation (reactive
gliosis) and neuroinflammation. Sildenafil treatment did not
reduce the levels of these proteins in mice without iNOS.
Western Blotting (WB) analysis showed that GFAP, a
marker of astrocyte activation (reactive gliosis), was present
in the cerebellum of untreated iNOS−/− animals (control)
(Figure 1(a)). Treatment with 0.2% cuprizone for four weeks
significantly increased expression of this protein (Figures 1(a)
and 1(c); 𝑃 < 0.001). Animals that concomitantly received
sildenafil (25mg/Kg) and cuprizone also exhibited a high
level of GFAP in comparison to control (Figures 1(a) and 1(c);
𝑃 < 0.001).
Immunofluorescence (IF) analysis of GFAP in the cere-
bellum revealed the expression and location of this cytoskele-
tal intermediate filament protein in the animals. In the
molecular layer of the cerebellum, GFAP labeling revealed
long astrocytic processes with a typical arrangement that was
perpendicular to the pia mater membrane (Bergmann glia)
(Figure 2(e)). Astrocytic processes were also seen around
other cells and vessels (arrowheads in Figures 2(b), 2(d), and
2(e)). The control group showed basal expression of GFAP
localized normally (Figures 2(a) and 2(d)). Treatment with
CPZ induced astrogliosis, increasing the intensity of labeling
in the astrocytes (Figures 2(b) and 2(e)). In the sildenafil
group, GFAP labeling was more intense than for control
(Figures 2(c) and 2(f)).
The iNOS−/− control group had a basal level of TNF-𝛼
(Figure 3(a)). WB analysis showed that cuprizone induced a
significant increase of this cytokine, indicating neuroinflam-
mation (Figures 3(a) and 3(b); 𝑃 < 0.05, compared to control
group). Animals that received cuprizone plus sildenafil also
had a significant increase of TNF-𝛼, compared to control
(𝑃 < 0.01).
COX-2 was analyzed by WB and immunohistochemistry
(IH) tests. This enzyme was expressed in a minimal amount
in the cerebellum of the iNOS−/− control group (Figures 3(c)
and 4(a)). CPZ administration induced a significant increase
in COX-2 expression, compared to control (Figures 3(c) and
3(d); 𝑃 < 0.01). Sildenafil treatment did not decrease COX-2,
which remained high in comparison with the control group
4 Mediators of Inflammation
GFAP 53 kDa
(a)
42 kDa
Cont CPZ CPZ + Sild
𝛽-Actin
(b)
0
50
100
150
200
Re
lat
iv
e e
xp
re
ss
io
n
co
m
pa
re
d 
to
 co
nt
ro
l
Cont CPZ + SildCPZ
∗∗∗
(c)
Figure 1: Western blotting for GFAP. (a) GFAP immunoblot of iNOS−/− control (Cont), cuprizone (CPZ), and cuprizone plus sildenafil
(CPZ + Sild) groups. (b) 𝛽-actin immunoblot. (c) Graph represents quantification and statistical analysis. The control group showed basal
expression of GFAP. CPZ treatment induced a significant increase of this protein and sildenafil plus CPZ did not reduce GFAP expression,
which remained higher in relation to the control group. The experiment was performed in triplicate (𝑛 = 5 animals/group). The results were
expressed as mean ± SE. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 compared to control.
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Figure 2: Immunofluorescence forGFAP. (a) and (d) show expression and physiological locations of GFAP inmicewithout iNOS andwithout
treatment. CPZ administration ((b), (e)) induced reactive gliosis, with thicker andmore numerous astrocytic processes, compared to control.
GFAP remained high in relation to control, after application of sildenafil plus CPZ ((c), (f)). Arrows show astrocytic processes and arrowheads
point to processes around vessels and other cells. W: white matter, M: molecular layer, P: purkinje layer, G: granular layer, and v: vessel. Bars:
20 𝜇m.
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Figure 3: Western blotting for TNF-𝛼 and COX-2. ((a), (c)) Immunoblots of iNOS−/− control (Cont), cuprizone (CPZ), and cuprizone plus
sildenafil (CPZ + Sild) groups. ((b), (d)) Graphs represent quantification and statistical analysis.The control group showed basal expression of
TNF-𝛼. CPZ treatment caused a significant increase of this cytokine, and sildenafil plus CPZ did not decrease its expression, which remained
higher in relation to the control group. Only minimum amounts of COX-2 were present in the control group. CPZ and CPZ + Sild caused a
significant increase of this enzyme, compared to control.The experiment was performed in triplicate (𝑛 = 5 animals/group).The results were
expressed as mean ± SE. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 compared to control.
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Figure 4: Immunohistochemistry for COX-2 ((a)–(c)) and immunofluorescence for Iba-1 ((d)–(f)). iNOS−/− control (a) showed very low
COX-2 expression (arrow). After CPZ treatment (b), COX-2 labeling significantly increased, mainly in white matter, in relation to control.
Animals treated with CPZ + Sild (c) also increased COX-2, comparing to the control group. A basal expression of Iba-1 was seen in control
animals without iNOS (d). CPZ increased Iba-1 and induced an activated phenotype (arrowheads) of microglia (e). Sildenafil plus CPZ
decreased Iba-1 and induced latent phenotype (arrows) of microglia (f).
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Figure 5: Western blotting for IL-1𝛽 and IFN-𝛾. ((a), (c)) Immunoblots of iNOS−/− control (Cont), cuprizone (CPZ), and cuprizone plus
sildenafil (CPZ + Sild) groups. ((b), (d)) Graphs represent quantification and statistical analysis. The control group showed basal expression
of IL-1𝛽 and IFN-𝛾. CPZ treatment induced a significant increase of these cytokines, compared to control. Sildenafil plus CPZ significantly
decreased IL-1𝛽 and IFN-𝛾 expression, in relation to the CPZ group. The experiment was performed in triplicate. The results were expressed
as mean ± SE. ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001, compared to control; ##𝑃 < 0.01, ###𝑃 < 0.001, compared with CPZ.
(Figures 3(c) and 3(d); 𝑃 < 0.01). IH labeling revealed the
expression and location of COX-2 (Figures 4(a)–4(c)), which
was mainly found in the white matter of the cerebellum.
The control group had a very low expression of this enzyme
(Figure 4(a)), while treated animals had a high expression of
COX-2 in white matter (Figures 4(b) and 4(c)).
Immunoblot control with 𝛽-actin is shown in Figure 1(b).
Cuprizone increased Iba-1, IL-1𝛽, and IFN-𝛾 expression
in the cerebellumof iNOS−/−mice.While sildenafil decreased
the expression of these proteins, the level of expression
remained above that of control animals.
The microglial marker, Iba-1, was analyzed by IF. There
was physiological expression of Iba-1 in the cerebellum of
iNOS−/− control animals, with cells with processes that
were typically branched, thin and weakly labeled (arrow,
Figure 4(d)). Cuprizone treatment induced a stronger expres-
sion of Iba-1 (Figure 4(e)), compared to the control group,
with thicker and more intensely labeled microglial processes.
These processes lost their typical thin branched appearance,
indicating that the cell phenotype had acquired activated
characteristics. Sildenafil together with CPZ decreased Iba-1
expression, and themicroglia exhibited thin, highly branched
processes, typical of a latent state (Figure 4(f)).
Immunoblotting for IL-1𝛽 and IFN-𝛾 revealed basal
expression of these cytokines in the iNOS−/− control group
(Figures 5(a) and 5(c)). Cuprizone strongly increased the
expression of these cytokines (both 𝑃 < 0.001), compared
to the control group (Figures 5(a)–5(d)), which indicates
neuroinflammation. Sildenafil treatment resulted in a signifi-
cant decrease of IL-1𝛽 and IFN-𝛾 compared to the cuprizone
group (𝑃 < 0.01). However, the levels of IL-1𝛽 and IFN-
𝛾 remained higher in the sildenafil-treated group when
compared with baseline levels of the control group (𝑃 < 0.01
and 𝑃 < 0.001, resp.).
Mice without iNOS underwent a significant increase in
eNOS expression, compared to wild-type animals.
Untreated mice iNOS−/− (control group; 𝑃 < 0.01) and
iNOS−/− animals treated with CPZ or CPZ + Sild (both
𝑃 < 0.001) showed a significant increase in eNOS levels,
compared with wild-type mice that did not undergo treat-
ment. The expression of eNOS in iNOS−/− mice treated with
CPZ and CPZ plus sildenafil was not significantly higher
when compared to iNOS−/− control animals but showed a
propensity to increase (Figures 6(a) and 6(b)).
Cuprizone decreased GSTpi, indicating the depletion of
mature oligodendrocytes. Sildenafil increased GSTpi expres-
sion in the cerebellum of iNOS−/− mice.
GSTpi, a marker of myelinating oligodendrocytes,
was expressed in the cerebellum of the control group
(Figure 7(a)). After treatment with CPZ, this marker
decreased significantly (𝑃 < 0.001) compared to the control
group, suggesting an impairment ofmature oligodendrocytes
and consequentmyelin damage. Sildenafil treatment together
with CPZ induced partial recovery of the GSTpi marker,
indicating that sildenafil had a protective effect on mature
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Figure 6: Western blotting for eNOS. (a) Immunoblot of wild-
type mice control (WT cont), iNOS−/− mice control (iNOS−/−
cont), iNOS−/− animals treated with cuprizone (iNOS−/− CPZ), and
iNOS−/− animals treated with cuprizone plus sildenafil (iNOS−/−
CPZ + Sild). (b) Graph represents quantification and statistical
analysis. eNOS was physiologically expressed in WTmice. Animals
without iNOS without treatment showed a significant increase of
this enzyme, compared to WT control. After CPZ and CPZ plus
sildenafil, iNOS−/− animals also showed a significant increase of
eNOS, compared to WT animals, but no significant difference
was identified between iNOS−/− control and treated animals. The
experiment was performed in triplicate. The results were expressed
as mean ± SE. ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001, compared to control.
oligodendrocytes. In the sildenafil group, GSTpi decreased
in comparison with control (𝑃 < 0.001) but increased in
comparison to the cuprizone group (𝑃 < 0.001; Figures 7(a)
and 7(b)).
Myelin sheath structure was disorganized in animals
without iNOS which did not undergo treatment (control).
Cuprizone induced more severe myelin disruption. Sildenafil
improved myelin structure and ultrastructure.
Interestingly, iNOS−/− animals without treatment (con-
trol) had moderate disorganization of the myelin structure
and ultrastructure (Figures 8(a), 8(d), and 8(g)). Standard
LFB staining showed that the control group iNOS−/− had
vacuoles in white matter (arrow in Figure 8(a)), resulting in
inhomogeneous and disorganized tissue. Qualitative analysis
of ultrathin cerebellum sections by TEM revealed that the
myelin sheath was often shredded, with blanks, and without
the characteristic lamellar pattern (arrows in Figures 8(d) and
8(g)).
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Figure 7: Western blotting for GSTpi. (a) Immunoblot of iNOS−/−
control (Cont), cuprizone (CPZ), and cuprizone plus sildenafil (CPZ
+ Sild) groups. (b) Graph represents quantification and statistical
analysis. iNOS−/− control showed basal expression of GSTpi. After
CPZ,GSTpi decreased significantly, compared to iNOS−/− cont. CPZ
+ Sild treatment increased GSTpi expression in relation to the CPZ
group, but the levels of this protein remained significantly decreased
compared to control. The experiment was performed in triplicate.
∗∗∗
𝑃 < 0.001 compared to control; ###𝑃 < 0.001 compared to CPZ.
Cuprizone-treated animals exhibitedmore severe damage
tomyelin structure and ultrastructure (Figures 8(b), 8(e), and
8(h)). LFB staining (Figure 8(b)) showed vacuoles (arrows)
and spaces (arrowhead) as slits in white matter, characteristic
of highly disorganized tissue. TEM revealed that CPZ caused
serious damage to the myelin sheath ultrastructure, which
had numerous spaces between the shreds in practically all
fibers (represented by arrows in Figures 8(e) and 8(h)). The
typical lamellar pattern was entirely absent.
Simultaneous treatment with sildenafil and CPZ resulted
in a noticeable improvement of myelin organization (Figures
8(c), 8(f), and 8(i)). White matter was more homogeneous,
presenting fewer and, in general, smaller vacuoles and slit-
like spaces (Figure 8(c)). Ultrathin section analysis revealed
a more preserved myelin sheath which rarely showed signs of
shredding.
4. Discussion
The cuprizone model is characterized by primary and
reversible demyelination, due to peripheral immune system-
independent myelin injury [25]. In this model, demyelina-
tion is accompanied by a well-characterized sequence of
events involving the depletion of mature oligodendrocytes,
microglia activation, and astrocyte proliferation [26]. There-
fore, demyelination and resident neuroinflammation induced
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0.5 𝜇m
(i)
Figure 8: Luxol Fast Blue (LFB) staining ((a)–(c)) and electron micrographs ((d)–(i)). (a), (d), and (g) represent iNOS−/− control group; (b),
(e), and (h) represent CPZ-treated animals; (c), (f), and (i) represent CPZ + Sild-treated animals. Arrows in (a), (c): vacuoles in the white
matter; arrowhead in (b): spaces between fibers; arrows in (d), (e), (g), and (h): damaged myelin sheath; arrowheads in (f), (i): preserved
myelin. Bars = 20𝜇m ((a)–(c)); 2𝜇m ((d)–(f)); 0.5 𝜇m ((g)–(i)).
by cuprizone in rodents have been widely used as a model
for MS [20, 27]. In the present study, the usefulness of
the cuprizone model is considerable as it allows evaluation
of the role of the iNOS/NO-sGC-cGMP pathway in the
inflammation and demyelination mediated by resident CNS
cells.
The cerebellum was chosen for analysis, as it is an impor-
tant CNS affected region in MS patients, revealing severe
whitematter atrophy [28, 29]. Furthermore, the authors of the
present study had recently investigated this region [22]. The
present data, relating to iNOS−/− animals, will be discussed
with reference to this previous study. Nunes et al. (2012)
[22] showed that in C57BL/6 wild-type (WT)mice cuprizone
induced tissue damage, increased GFAP, Iba-1, and COX-
2 expression, and caused demyelination, in comparison to
the control group. However, cuprizone did not affect the
expression of cytokines (TNF-𝛼, IFN-𝛾, IL-1𝛽, and IL-2) in
WT mice. In the previous study by the authors, sildenafil
reduced GFAP and Iba-1 expression in comparison to the
cuprizone group, preserved myelin and axon ultrastructure,
and significantly downregulated IFN-𝛾, TNF-𝛼, IL-1𝛽, IL-2,
and COX-2 expression in comparison to the control and/or
cuprizone groups. The previous results demonstrated the
protective effect of sildenafil on the cerebellum. Sildenafil
promotes the accumulation of cGMP, which is the main
NO signaling molecule. It was considered important to
investigate the role of NO in the MS-model and the effects
of sildenafil more profoundly.Therefore, in the present study,
the relationship between iNOSnull mice, the MS-model, and
the effects of sildenafil in the cerebellum was investigated.
In the absence of iNOS/NO, cuprizone significantly
increased expression of GFAP, TNF-𝛼, COX-2, Iba-1, IL-1𝛽,
and IFN-𝛾. In addition, cuprizone intoxication decreased
GSTpi, a marker for myelinating oligodendrocytes, damaged
myelin, and induced tremors, abnormal walking, and pos-
ture.This data indicates that cuprizone intoxication occurred
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even without the iNOS-NO system and was stronger than in
WTmice, where cuprizone did not increase cytokine expres-
sion [22]. Interestingly, iNOS−/− control animals showed an
altered myelin structure.
It was hypothesized that, in the absence of iNOS,
eNOS may be overexpressed as a compensatory mecha-
nism. Bernardini et al. [30] showed that treatment with
endotoxin influenced NOS expression, upregulating iNOS
and, simultaneously, downregulating eNOS. There appeared
to be a regulatory relationship between the expression of
iNOS and eNOS. In fact, it was found here that eNOS
was strongly expressed in iNOS−/− animals in comparison
with WT mice. The eNOS levels remained high after the
administration of cuprizone and cuprizone plus sildenafil.
In normal conditions, low levels of NO produced by both
eNOS and nNOS participate in cell signaling and regulate
physiologic processes [31]. However, eNOS overexpression
(and consequently, constant high concentration of NO) can
be responsible for myelin changes and proinflammatory
susceptibility in iNOS−/− animals.
On the other hand, iNOS possesses an important feed-
back mechanism in inflammatory conditions, when the
increase of this enzyme is self-regulated, and induces a reduc-
tion of some proinflammatory proteins [32–35]. The inhibi-
tion of iNOS activity induces enhancement of IL-1𝛽, IL-6,
andTNF-𝛼 levels [36] and, subsequently, a persistent increase
of iNOS expression, downregulating the TNF receptor [35].
In the present study, absence of iNOS may explain increased
TNF-𝛼, IFN-𝛾, and IL-1 after cuprizone treatment in iNOS−/−
mice, while cuprizone did not increase these cytokines inWT
mice [22]. This feedback mechanism is coregulated by a high
concentration of cGMP [32]. Therefore, another hypothesis
for explaining the more severe inflammation induced by
cuprizone in mice without iNOS is the absence of iNOS
feedback mechanism.
Interestingly, although sildenafil had a low anti-inflam-
matory effect on iNOS−/− mice, it considerably improved
the myelin structure of mice without iNOS. Cuprizone is
a copper chelator which leads to direct oligodendrocyte
death with subsequent demyelination [37]. In this model,
oligodendrocyte death and demyelination are independent of
immune and inflammatory response. It was found that cGMP
analog (8-Br-cGMP) protects differentiated oligodendrocytes
from death initiated by staurosporine, thapsigargin, or
kainate [38]. It is possible that sildenafil, through the
accumulation of cGMP, has a direct beneficial effect on
oligodendrocytes, protecting these cells and improving
myelination, independent of its anti-inflammatory effects.
In conclusion, the findings of the present study show that
iNOS−/− mice are more susceptible to cuprizone intoxication
due to the potential involvement of two mechanisms: (1)
iNOS-negative feedback mechanism in inflammatory condi-
tions is absent and, consequently, proinflammatory proteins,
such as cytokines and COX-2, are excessively increased; (2)
eNOS is overexpressed by a compensatory mechanism and
generates chronically high levels of NO, damaging the tissue.
Also, the results of the present study suggest that sildenafil
may exert its anti-inflammatory effects mainly through iNOS
inhibition, by cGMP-iNOS feedback. In addition, sildenafil
may have a direct protective effect on oligodendrocytes. Fur-
ther studies are required to explain themolecularmechanism
of sildenafil protection in the central nervous system.
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